BioAtla, Inc

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioAtla reports positive trial results and financial stability in Q4

BioAtla's Q4 2022 earnings call highlighted positive trial results, strong financial position, and progress in clinical development efforts
While facing challenges such as increased R&D expenses and enrollment hurdles, the company remains focused on innovation and patient safety
Opportunities lie in leveraging dosing regimens for enhanced efficacy, responding to patient needs, and updating stakeholders on future advancements

BioAtla reports positive clinical responses and solid financial position

BioAtla showcased strong clinical progress in Phase 2 trials, with positive responses in various cancer indications. Despite financial losses, the company maintains a solid cash position. Challenges lie in optimizing dosing and balancing characteristics in combination therapies, while opportunities exist in furthering combination therapy research and FDA interactions.

BioAtla reports progress in novel cancer therapies and financial stability

BioAtla is making significant strides in developing novel therapies for solid tumor types with high unmet medical needs.
The company's financial position is stable with plans to fund operations into 2025 and explore strategic partnerships.
Challenges include managing R&D expenses, rolling out liquid biopsy to other indications, and optimizing combination therapy approaches.
Opportunities lie in potential corporate development, strategic partnerships, and expanding treatment options with promising combination therapies.

BioAtla reports positive clinical trial results and strong financial position

BioAtla showcased promising clinical trial results for BA3011 and BA3021, with a focus on delivering innovative therapies for cancer treatment. Despite increased expenses and a net loss in Q3 2023, the company maintains a strong financial position and aims to maximize shareholder value through strategic collaborations and advancements in its pipeline.

BioAtla reports strong clinical progress and financial review in Q4

BioAtla's Q4 2023 earnings call highlighted substantial progress in clinical programs, financial performance, and strategic plans for future growth.
The company's focus on advancing CAB programs, innovative therapies, and collaborations underscores its commitment to driving clinical and commercial success.
While facing challenges in regulatory processes and trial execution, BioAtla remains well-positioned to leverage opportunities for market expansion and therapeutic innovation.

BioAtla reports positive clinical data and financial progress in Q1 2024 earnings call

BioAtla's Q1 2024 Earnings Call showcased positive clinical data, financial improvements, and strategic advancements in its pipeline.
The company's focus on safety, enthusiasm from leadership, and plans for future trials indicate a promising outlook for its drug development programs.
While facing challenges in differentiation, safety management, and financial sustainability, BioAtla remains poised to capitalize on market opportunities and collaborations.

BioAtla reports robust Q3 earnings with promising oncology pipeline progress

BioAtla's Q3 2024 earnings call highlighted strong financial performance and significant advancements in their oncology pipeline, supported by positive clinical data and regulatory feedback.
The company's focus on key compounds like ozuriftamab vedotin and evalstotug in various cancer types positions them well for future growth and potential commercial success.
While challenges in clinical trial execution and regulatory complexities exist, BioAtla has opportunities to capitalize on FDA support, expand indications, and drive innovation in precision oncology.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and in combination with a PD-1 inhibitor SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent.

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day on Wednesday, December 13, 2023 at 10:00 AM ET. To register, click here.

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and scheduled one-on-one investor meetings at the JMP Securities Hematology and Oncology Summit, to be held virtually December 5–6, 2023.

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual KOL Event on Monday, December 4, 2023 at 11:00 AM ET. To register, click here.

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

BioAtla, Inc. (NASDAQ:BCAB ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Dev Prasad - Jefferies Arthur He - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call.

BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided an update on its clinical programs.

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 14–16, 2023.

BioAtla to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D.

BioAtla's Jay M. Short, Ph.D.

SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today provided guidance on near-term milestones and announced that it plans to host a conference call and webcast on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2023 and provide business highlights.

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023.

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in two upcoming investor conferences, to be held in August 2023.

BioAtla to Participate in Upcoming Investor Conferences in August

BioAtla, Inc. (NASDAQ:BCAB ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman & Chief Medical Officer Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Arthur He - H.C. Wainwright Tony Butler - E.F.

BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript

SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and provided highlights on its clinical programs.

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, August 1, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023 and provide business highlights.

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company has been added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. markets open on June 26, 2023, as part of the 2023 Russell indexes reconstitution in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.

BioAtla to Participate in the Jefferies Healthcare Conference

BioAtla, Inc. (NASDAQ:BCAB ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman and CEO Richard Waldron - CFO Philippe Martin - Chief CDO Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Reni Benjamin - JMP Securities Arthur He - H.C. Wainwright Operator Greetings.

BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2023, and provided highlights on its clinical programs.

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate in one-on-one investor meetings at the JMP Securities Life Sciences Conference, to be held in New York, NY, from May 15-16, 2023.

BioAtla to Participate in the JMP Securities Life Sciences Conference

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide business highlights.

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

BioAtla, Inc. (NASDAQ:BCAB ) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Philippe Martin - Chief Clinical Development and Operations Conference Call Participants Brian Cheng - JPMorgan Kelly Shi - Jefferies Tony Buter - EF Hutton Arthur He - H.C. Wainwright Reni Benjamin - JMP Securities Operator Greetings.

BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript

- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2022 and provide business highlights.

BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as Chief Executive Officer at Viatris (Nasdaq: VTRS), a large, global healthcare pharmaceutical company. Scott will continue his relationship with BioAtla by serving as a Board of Directors member for the Company.

News for BioAtla, Inc Stock (BCAB)